
Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.
Explore how type 2 inflammation drives sinonasal barrier dysfunction in chronic rhinosinusitis with nasal polyps (CRSwNP) with this video on the cellular mechanisms behind hallmark symptoms — including nasal congestion and loss of smell.

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

This infographic highlights the clinical burden of Allergic Fungal Rhinosinusitis (AFRS), including disease severity, recurrence, complications, and impact on patients compared with CRSwNP.
Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
Learn from Drs. Buchheit and Wagenmann as they discuss key patient traits that predict disease recurrence in CRSwNP.
Join Sanofi and Regeneron for four educational symposia on asthma, COPD, and the unified airway.